|
NLPHL |
LRCHL |
T/HRBCL |
Clinical presentation |
53 percent Stage I |
46 percent Stage I |
8 percent Stage I |
28 percent Stage II |
24 percent Stage II |
8 percent Stage II |
14 percent Stage III |
24 percent Stage III |
15 percent Stage III |
6 percent Stage IV |
6 percent Stage IV |
69 percent Stage IV |
10 percent B symptoms |
10 percent B symptoms |
54 percent B symptoms |
Neoplastic cells |
L&H cell |
Reed-Sternberg cell which can resemble L&H cells or lacunar cells |
Can resemble the L&H cell, centroblast, immunoblast, or Reed-Sternberg cell |
Background cells |
B cells >T cells small B cells, CD3+CD4+CD57+ T cells and follicular dendritic cells |
Variable. In nodular cases, Reed-Sternberg cells may be found adjacent to B cell follicles |
T cells >B cells CD8+ cytotoxic T cells and histiocytes |
Growth pattern |
Nodular, at least in part |
Usually nodular but can be diffuse |
Usually diffuse |
Tumor cell immunophenotype |
CD15 |
- |
+ |
- |
CD30 |
-/+ |
+/- |
-/+ |
CD20 |
+ |
-/+ |
+ |
CD45 |
+ |
- |
+ |
EMA |
+/- |
- |
+/- |
BOB-1 |
+ |
-/+ |
+ |
OCT-2 |
+ |
-/+ |
+ |
BLC6 |
+ |
-/+ |
+/- |